The Group's principal activity is to discover, develop and commercialize potential drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The Group has two approved products, BYETTA(R) (exenatide) injection, and SYMLIN(R) (pramlintide acetate) injection, both of which were commercially launched in the United States in 2005. BYETTA is the first and only approved medicine in a new class of compounds called incretin mimetics. SYMLIN is the first and only approved medicine in a new class of compounds called amylinomimetics. The Group has a global development and commercialization agreement for exenatide, including BYETTA and any sustained-release formulations of BYETTA, including exenatide LAR, with Eli Lilly & Company.
Research Alerts:
Receive alerts on the latest reports on Amylin Pharmaceuticals, Inc.
Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
